Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using its proprietary ddRNAi platform, which combines RNA interference with gene therapy to silence disease-causing genes and restore normal protein function through a single-administration approach. The company's lead product candidate, BB-301, is designed to treat oculopharyngeal muscular dystrophy (OPMD), a rare progressive neuromuscular disorder caused by gene mutation, and is currently in Phase 1b/2a clinical trials using modified AAV9 vectors for direct delivery to affected muscles. Benitec generates value through its intellectual property portfolio covering proprietary constructs, vector designs, and delivery methods, with plans to commercialize approved products through strategic partnerships or direct marketing while outsourcing manufacturing to third-party partners.